Arcellx
NASDAQ · ACLX·Redwood City, CA·Mid-cap·Phase 3
Clinical-stage biotech engineering CAR-T cell therapies for cancer and other diseases. Lead asset anito-cel (anitocabtagene autoleucel) is a BCMA-directed CAR-T in pivotal trials for relapsed/refractory multiple myeloma, partnered with Kite/Gilead.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Arcellx January 2026 Corporate Presentation | Corporate overview | January 1, 2026 | 65 |